Faeth Therapeutics, Inc.(FTH)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$10.03
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for FTH

11/13/2026: FTH (1-star) is currently NOT-A-BUY. Pass it for now.

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted oncology therapies and pathway inhibitors such as PIKTOR. The company's primary strength lies in its innovative pipeline targeting difficult-to-treat solid tumors, presenting an investment story driven by potential clinical trial catalysts. However, as a pre-revenue firm, it faces substantial execution, financial burn, and high competition risks typical of early-stage biotech stocks. The stock suits growth-oriented investors with high risk tolerance who can monitor clinical milestones. Prospective investors should closely track upcoming trial readouts and capital liquidity developments.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveIt offers high-beta exposure to clinical-stage oncology pipeline catalysts and potential breakthrough therapies.
Momentum investorStrong fit while signal remains positiveThe stock can experience sharp price movements driven by clinical trial readouts, making it conditional on a positive momentum upturn signal.
Value investorWeak fitThe absence of current earnings or commercial revenue makes traditional value metrics inapplicable.
Dividend investorWeak fitThe company retains all capital to fund clinical trials and does not pay dividends.
Low-risk investorWeak fitHigh clinical development risks and share price volatility present a risk profile unsuited for conservative investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotechnology stocks frequently experience dramatic price swings around trial results and financing events.
Valuation riskHighValuations are driven by speculative future pipeline potential rather than current financial earnings.
Competition risk (oncology therapeutics)HighThe company competes with well-funded major pharmaceutical companies developing similar cancer treatments.
Business qualityMediumWhile scientific expertise is high, the business model remains pre-revenue and dependent on developmental success.
Dividend incomeLow / noneNo dividend is paid or anticipated in the near term.
Execution riskHighSuccess relies entirely on successfully executing complex clinical trials and securing regulatory approvals.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 259.21M USD
Price to earnings Ratio -
1Y Target Price 56.15
Price to earnings Ratio -
1Y Target Price 56.15
Volume (30-day avg) 593.1K shares
Beta -0.18
52 Weeks Range 7.45 - 42.14
Updated Date 11/15/2026
52 Weeks Range 7.45 - 42.14
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -22.5

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -59.65%
Avg. Invested days 20
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
FTH receives a 3-star rating, supported by solid company fundamentals, and strong analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
FTH has solid overall fundamentals (4 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, solid earnings growth (+30.1%) is partially offset by soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%), soft profitability (net margin 0.0%).

Financial Health Rating

★★★★★
FTH's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is FTH's strongest growth driver at +30.1% FY2025 versus FY2024 (solid, 4 stars). By comparison, free-cash-flow growth (+17.5%, solid) is also solid, while revenue growth (+0.0%, slightly negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 81.1% and approximately 71.6% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 4.95% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Suvretta Capital Management, LLC 7.82%
venBio Select Advisor LLC 5.59%
Baker Bros Advisors LP 4.98%
Balyasny Asset Management LLC 4.03%
Cormorant Asset Management, LLC 3.98%

Unit Economics (Per $1K Revenue)

★★★★★
FTH generates approximately $0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
FTH has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical-Stage Oncology PipelineFuture commercialization milestones, product licensing agreements, and potential drug sales upon regulatory approval of pipeline assets.The company does not currently sell commercial products and relies on capital raises and partnerships while advancing drugs through clinical trials.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 84.56M
Price to Sales(TTM) -
Enterprise Value 84.56M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 1.36
Shares Outstanding 25.84M
Shares Floating 18.51M
Shares Outstanding 25.84M
Shares Floating 18.51M
Percent Insiders 4.95
Percent Institutions 81.11

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.